We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Drug Developers Identify Novel Target for Treatment of Autoimmune Disease

By LabMedica International staff writers
Posted on 05 May 2009
A recent study identified the target molecule for quinoline-3-carboxamides (Q compounds), a class that developers of drugs for treatment of autoimmune and inflammatory diseases have been working with for more than 25 years.

Q compounds have proven effective in clinical trials for the treatment of multiple sclerosis (MS) and type I diabetes. More...
Furthermore, they are currently in phase III clinical development for the treatment of MS and are about to enter phase II for the treatment of systemic lupus erythematosus (SLE). However, despite intensive research efforts, the target molecule and the mode of action of this class of compounds have remained unknown for over 25 years.

Q compounds are unique in that they have a potent effect on disease development in several animal models of autoimmune or inflammatory disease without inducing suppression of adaptive immunity. In the current study, investigators from Lund University (Sweden), the University of Muenster (Germany), and the company Active Biotech AB (Lund, Sweden) successfully identified a molecular target for quinoline compounds.

The investigators reported in the April 28, 2009, online edition of the journal PLoS Biology that the target was a protein called S100A9. This protein belongs to the family of calcium-binding S100 proteins and has been extensively studied. It is expressed in granulocytes and at early stages of monocyte differentiation. S100A9 has also been detected on the cell surface of mouse macrophages at sites of inflammation, but the role of surface-bound S100A9 in immunity and inflammation is still unclear.

In the current study, the investigators revealed that S100A9 interacted with two known proinflammatory receptors (Toll-like receptor 4 [TLR4] and receptor of advanced glycation end products [RAGE]), and that this interaction was inhibited by quinoline compounds.

These findings allowed the authors to conclude that, " S100A9 appears to be a focal molecule in the control of autoimmune disease via its interactions with proinflammatory mediators. The specific binding of quinoline-3-carboxamides to S100A9 explains the immunomodulatory activity of this class of compounds and defines S100A9 as a novel target for treatment of human autoimmune diseases."

Active Biotech AB currently has three experimental quinoline drugs (laquinimod, 57-57, and TASQ) under active investigation.

Related Links:

Lund University
University of Muenster
Active Biotech



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Urine Analyzer
respons® UDS100
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.